Wyeth drops top trial dosage of Alzheimer’s drug

Wyeth and Elan Corp. said today that they stopped the top dosage in their trial of bapineuzumab, an experimental treatment for Alzheimer's, because participants are suffering from an increased risk of brain inflammation from water retention.